Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Non-Current Debt (2016 - 2025)

Haemonetics has reported Non-Current Debt over the past 16 years, most recently at $920.0 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $920.0 million for Q4 2025, down 24.58% from a year ago — trailing twelve months through Dec 2025 was $920.0 million (down 24.58% YoY), and the annual figure for FY2025 was $921.2 million, up 15.51%.
  • Non-Current Debt for Q4 2025 was $920.0 million at Haemonetics, roughly flat from $920.4 million in the prior quarter.
  • Over the last five years, Non-Current Debt for HAE hit a ceiling of $1.2 billion in Q4 2024 and a floor of $559.4 million in Q2 2022.
  • Median Non-Current Debt over the past 5 years was $765.2 million (2021), compared with a mean of $843.8 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 158.46% in 2021 and later fell 24.58% in 2025.
  • Haemonetics' Non-Current Debt stood at $698.0 million in 2021, then grew by 8.42% to $756.8 million in 2022, then rose by 13.22% to $856.8 million in 2023, then surged by 42.35% to $1.2 billion in 2024, then fell by 24.58% to $920.0 million in 2025.
  • The last three reported values for Non-Current Debt were $920.0 million (Q4 2025), $920.4 million (Q3 2025), and $920.8 million (Q2 2025) per Business Quant data.